

# BIONIK

## Company Overview

BIONIK is a global pioneering healthcare company on a mission to supply quality-of-life solutions to those with movement impairments.

Our goal is to enable the growing millions of people with movement-impairments to lead fuller and more independent lives by fostering hope, recovery and independence with evidence-based technologies, spanning the continuum of rehabilitation care.

The Company's product portfolio includes three InMotion Robots for rehabilitation following stroke and other neurological conditions and four products in varying stages of development. Resulting from groundbreaking research at the Newman Laboratory for Biomechanics and Human Rehabilitation at the Massachusetts Institute of Technology (MIT), the InMotion robots provide effective, patient-adaptive therapy, intended to restore upper-extremity motor control for a broad range of neurological conditions and recovery stages, including early recovery from acute stroke.

The InMotion Robots also provide objective evaluation assessments intended to measure and report the patient's level of motor impairment and progress during the course of therapy. A home version of the InMotion upper-extremity technology is in development, as well as a wearable, lower-extremity, assistive product based on the company's ARKE exoskeleton technology. Targeted for the consumer market, the ARKE-based assistive device is intended to help certain individuals walk better.

## BIONIK Laboratories Second Quarter Fiscal 2019 Financial Results Feature 147% Increase in Revenues

Nov 13 2018, 7:31 AM EST

## Bionik Laboratories Files Registration Statement for Proposed Follow-On Offering

Oct 30 2018, 7:32 AM EDT

## Bionik Laboratories Announces 1-for-150 Reverse Stock Split

Oct 29 2018, 4:01 PM EDT

## Stock Overview

Symbol	BNKLD
Exchange	OTCQB
Market Cap	15.18m
Last Price	\$6.50
52-Week	\$1.00 - \$27.375

11/16/2018 09:30 AM EST

## Investor Relations

Leslie Markow CPA CA CPA (Illinois)
C. Dir.
Chief Financial Officer
T: 416 402-3694
<a href="mailto:lm@bioniklabs.com">lm@bioniklabs.com</a>

## Management Team

### Eric Dusseux, MD, MSc, MBA

Chief Executive Officer

### Michael Prywata

Co-Founder and Chief Technology Officer

### Leslie N. Markow, CPA, CA, CPA (Illinois), C.Dir.

Chief Financial Officer

### Renaud Maloberti

Chief Commercial Officer

### Malcolm G. Bock

Vice President of Engineering

## Bionik Laboratories Corp.

483 Bay Street

Office N105

Toronto, ON M5G 2C9

Canada

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.

